Top-line phase II data for Abcellera Biologics Inc.’s ABCL-635, an injectable candidate for menopausal hot flashes, blew past company and investor expectations Aug. 10, sending the company’s shares up nearly 35%. Company shares (NASDAQ:ABCL) soared, ending the day Aug. 10 at $9.34, up $2.41, or 34.8%. TYK2 inhibitor holding steady for Alumis in psoriasis phase IIIAlumis Inc. disclosed positive top-line 48-week data from the ongoing phase III Onward3 long-term extension study with oral tyrosine kinase 2 (TYK2) inhibitor envudeucitinib in psoriasis. Multidrug-resistant Candida auris persists in hair folliclesWhy is Candida auris so difficult to eliminate? “We were comparing Candida auris to Candida albicans, which until now has been the best-studied fungus on skin, and it is not very efficient at colonizing skin.